TRACON Pharmaceuticals to Present at Upcoming Investment Conferences

SAN DIEGO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals TCON, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the following investor conferences in November:

Stifel 2017 Healthcare Conference

Tuesday, November 14 at 4:15 PM EST at the Lotte New York Palace Hotel in New York, NY

Jefferies 2017 London Healthcare Conference

Thursday, November 16 at 12:40 PM GMT (7:40 AM EST) in London, UK

To access live webcasts of the presentations, please visit the "Events and Presentation" section within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcasts will be available on the website for 60 days following the events.

About TRACON

TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company's clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Company Contact:

Casey Logan

Chief Business Officer

(858) 550‐0780 ext. 236

clogan@traconpharma.com

Investor Contact:

Andrew McDonald

LifeSci Advisors LLC

646-597-6987

Andrew@lifesciadvisors.com